Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Serological characteristics and immunohematological difficulties in autoimmune hemolytic anemia patients: A retrospective analytical study from South India.
Asian J Transfus Sci
September 2022
Department of Transfusion Medicine, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India.
Introduction: Autoimmune hemolytic anemia (AIHA) is a condition in which there is decreased survival of red blood cells (RBC) due to the destruction of RBC by autoantibodies. AIHA is classified into warm, cold, and mixed according to temperature sensitivity. The antibodies may be immunoglobulin G, immunoglobulin M, immunoglobulin A, or complement proteins, and hemolysis may be intravascular or extravascular.
View Article and Find Full Text PDFComparison of [F]FAPI-42 and [F]FDG PET/CT in the evaluation of systemic vasculitis.
Eur J Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, 510010, China.
Article Synopsis
- The study investigates the effectiveness of a new imaging technique, fluorine-18-labeled FAP inhibitor (FAPI-42), for detecting systemic vasculitis in patients, comparing it to the standard FDG imaging technique.
- A retrospective analysis of 30 patients revealed that FAPI-42 had a higher detection rate for lesions (100% vs. 93.3%) and identified more lesions overall compared to FDG (161 vs. 145).
- FAPI-42 also showed a moderate correlation with inflammatory markers, suggesting it may be a valuable tool for assessing systemic vasculitis severity.
Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.
Int J Mol Sci
November 2024
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
Paroxysmal Nocturnal Hemoglobinuria (PNH) constitutes a rare bone marrow failure syndrome characterized by hemolytic anemia, thrombotic events (TEs), and bone marrow aplasia of variable degrees. Thrombosis is one of the major clinical manifestations of the disease, affecting up to 40% of individuals with PNH. Venous thrombosis is more prevalent, affecting mainly unusual sites, such as intrabdominal and hepatic veins.
View Article and Find Full Text PDFA novel small molecule phagocytosis inhibitor, KB-208, ameliorates ITP in mouse models with similar efficacy as IVIG.
Transfusion
December 2024
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Background: The characteristic feature of immune cytopenias involves the process of extravascular phagocytosis, wherein macrophages in the spleen and/or liver engage in the destruction of blood cells that have been opsonized by auto- or alloantibodies. Therefore, new treatments that prevent phagocytosis will be advantageous, especially for short-term usage along with alternative options.
Study Design And Methods: KB-208, a small molecule drug, previously shown to be efficacious for the in vitro inhibition of phagocytosis was synthesized.
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Blood
November 2024
Mayo Clinic, Rochester, Minnesota, United States.
Article Synopsis
- This study tested pegcetacoplan, a targeted therapy aimed at treating these conditions, over 48 weeks in two patient groups with CAD and wAIHA who received either 270 or 360 mg/day.
- Results showed that pegcetacoplan was generally well tolerated with minimal serious side effects, and it effectively increased hemoglobin levels and reduced hemolysis in both groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!